Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis

Abstract

Lymph node dissemination is a major prognostic factor in human cancer. However, the molecular mechanisms underlying lymph node metastasis are poorly understood. Recently, vascular endothelial growth factor-C (VEGF-C) was identified as a ligand for VEGF receptor-3 (VEGFR-3/Flt-4) and the expression of VEGFR-3 was found to be highly restricted to the lymphatic endothelial cells. In this report, we investigated the expression of VEGF-C and VEGFR-3 in human prostatic carcinoma tissue by using in situ hybridization and immunohistochemical staining respectively. Expression of VEGF-C mRNA in prostatic carcinoma was significantly higher in lymph node-positive group than in lymph node-negative group. In addition, the number of VEGFR-3-positive vessels was increased in stroma surrounding VEGF-C-positive prostatic carcinoma cells. These results suggest that the expression of VEGF-C in prostatic carcinoma cells is implicated in the lymph node metastasis.

References 22

1. 1.

   Achen M. G., Jeltsch M., Kukk E., Mäkinen T., Vitali A., Wilks A. F., Alitalo K., Stacker S. A. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A. 1998;95(2):548-553.

   Not in our library10.1073/pnas.95.2.548

2. 2.

   Adams J. C. Heavy metal intensification of DAB-based HRP reaction product. J Histochem Cytochem. 1981;29(6):775-775.

   Not in our library10.1177/29.6.7252134

3. 3.

   Barleon B., Sozzani S., Zhou D., Weich H. A., Mantovani A., Marmé D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996;87(8):3336-3343.

   Not in our library

4. 4.

   Clauss M., Weich H., Breier G., Knies U., Röckl W., Waltenberger J., Risau W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem. 1996;271(30):17629-17634.

   Not in our library10.1074/jbc.271.30.17629

5. 5.

   Dvorak H. F., Brown L. F., Detmar M., Dvorak A. M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146(5):1029-1039.

   Not in our library

6. 6.

   Epstein J. I., Partin A. W., Sauvageot J., Walsh P. C. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol. 1996;20(3):286-292.

   Not in our library10.1097/00000478-199603000-00004

7. 7.

   Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18(1):4-25.

   Not in our library10.1210/edrv.18.1.0287

8. 8.

   Folkman J., Shing Y. Angiogenesis. J Biol Chem. 1992;267(16):10931-10934.

   Not in our library

9. 9.

   Fong G. H., Rossant J., Gertsenstein M., Breitman M. L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 1995;376(6535):66-70.

   Not in our library10.1038/376066a0

10. 10.

    Jeltsch M., Kaipainen A., Joukov V., Meng X., Lakso M., Rauvala H., Swartz M., Fukumura D., Jain R. K., Alitalo K. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science. 1997;276(5317):1423-1425.

    Not in our library10.1126/science.276.5317.1423

11. 11.

    Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., Saksela O., Kalkkinen N., Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15(2):290-298.

    Not in our library

12. 12.

    Jussila L., Valtola R., Partanen T. A., Salven P., Heikkilä P., Matikainen M. T., Renkonen R., Kaipainen A., Detmar M., Tschachler E. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res. 1998;58(8):1599-1604.

    Not in our library

13. 13.

    Kaipainen A., Korhonen J., Mustonen T., van Hinsbergh V. W., Fang G. H., Dumont D., Breitman M., Alitalo K. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A. 1995;92(8):3566-3570.

    Not in our library10.1073/pnas.92.8.3566

14. 14.

    Koji T., Nakane P. K. Recent advances in molecular histochemical techniques: in situ hybridization and southwestern histochemistry. J Electron Microsc (Tokyo). 1996;45(2):119-127.

    Not in our library10.1093/oxfordjournals.jmicro.a023420

15. 15.

    Oh S. J., Jeltsch M. M., Birkenhäger R., McCarthy J. E., Weich H. A., Christ B., Alitalo K., Wilting J. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol. 1997;188(1):96-109.

    Not in our library10.1006/dbio.1997.8639

16. 16.

    Pajusola K., Aprelikova O., Korhonen J., Kaipainen A., Pertovaara L., Alitalo R., Alitalo K. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res. 1992;52(20):5738-5743.

    Not in our library

17. 17.

    Shalaby F., Rossant J., Yamaguchi T. P., Gertsenstein M., Wu X. F., Breitman M. L., Schuh A. C. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376(6535):62-66.

    Not in our library10.1038/376062a0

18. 18.

    Slack N. H., Lane W. W., Priore R. L., Murphy G. P. Prostatic cancer. Treated at a categorical center, 1980-1983. Urology. 1986;27(3):205-213.

    Not in our library10.1016/0090-4295(86)90276-1

19. 19.

    Steiner M. S. Role of peptide growth factors in the prostate: a review. Urology. 1993;42(1):99-110.

    Not in our library10.1016/0090-4295(93)90352-b

20. 20.

    Tsurusaki T., Koji T., Sakai H., Kanetake H., Nakane P. K., Saito Y. Cellular expression of beta-microseminoprotein (beta-MSP) mRNA and its protein in untreated prostate cancer. Prostate. 1998;35(2):109-116.

    Not in our library10.1002/(sici)1097-0045(19980501)35:2<109::aid-pros4>3.0.co;2-e

21. 21.

    Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., Heldin C. H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem. 1994;269(43):26988-26995.

    Not in our library

22. 22.

    Yoshii A., Koji T., Ohsawa N., Nakane P. K. In situ localization of ribosomal RNAs is a reliable reference for hybridizable RNA in tissue sections. J Histochem Cytochem. 1995;43(3):321-327.

    Not in our library10.1177/43.3.7532657

Cited by papers we hold 3

• Correlation of Vascular Endothelial Growth Factor subtypes and their receptors with melanoma progression: A next-generation Tissue Microarray (ngTMA) automated analysis. · 2018
  Not checked
• The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer · 2001
  No notice
• Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues · 2000
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.